Why 10X Health, REVIV, and M42 chose Abu Dhabi to launch the world’s most advanced nutrition system

In a bold step that could reshape the global precision wellness and longevity sector, biotechnology company 10X Health, UK-based IV therapy specialist REVIV Global, and AI-driven healthcare conglomerate M42 have announced a strategic three-way partnership to launch a new initiative called 10XREVIV in Abu Dhabi. Anchored by a patented life sciences platform and backed by years of genetic, biomarker, and artificial intelligence innovation, the venture positions Abu Dhabi at the forefront of global efforts to integrate personalised health, genomics, and clinical-grade nutrition delivery.

The initiative introduces a full-stack model for precision health optimisation, leveraging a unique convergence of genetic science, lifestyle analytics, blood biomarker inputs, and AI-powered recommendations. It aims not only to provide hyper-personalised health recommendations but to clinically deliver these through regulated, data-informed therapies such as tailored IV infusions and supplement protocols.

This partnership comes at a time when the global personalised wellness industry is pivoting from generic, lifestyle-based claims toward science-backed models. With precision nutrition now emerging as a strategic frontier in healthcare innovation, the launch of 10XREVIV is more than just a product introduction—it is an infrastructural bet on the longevity economy, with implications for diagnostics, chronic disease management, and wellness-as-a-service business models.

Why is this partnership reshaping the landscape of personalised wellness and health optimisation?

The launch of 10XREVIV integrates the distinctive strengths of three specialised organisations. 10X Health brings a biotechnology backbone built on over a decade of genetic and systems biology research. REVIV Global contributes global clinical delivery expertise with over three million IV infusions administered in more than 40 countries. M42 offers the regional infrastructure and scale, with over 480 healthcare facilities spanning 26 countries, supported by deep AI, genomics, and predictive health capabilities.

At the heart of this collaboration is the 10X Precision Nutrition System, a proprietary engine developed by 10X Health to analyse up to 20 million genetic variants with a reported accuracy of 99.97 percent. These insights are integrated with blood chemistry data and lifestyle factors to generate a highly detailed, secure health profile exceeding 400 pages. The resulting recommendations are then translated into action via three key products: 10X Precision Supplements, 10X Precision Weight Management plans, and genetically guided IV therapies.

The supplements are formulated as micro-bead encapsulated nutrients, each precisely calibrated for an individual’s genetic profile across 22 core micronutrients. Weight management protocols go beyond calories, leveraging metabolic and genetic markers to recommend specific macronutrient distributions. Meanwhile, the IV therapies—offered only in approved clinical environments—deliver bioavailable nutrients based on the patient’s specific deficiencies, risk factors, and genome-derived needs.

By embedding these into a medically supervised, closed-loop care pathway, the partnership is aiming for clinical-grade outcomes, not just lifestyle improvements. This approach reflects the industry’s shift toward regulated wellness, where efficacy, traceability, and patient compliance are as critical as branding and user experience.

How does this launch reflect broader trends in the global health, biotech, and longevity markets?

The 10XREVIV platform arrives at a time when consumers, investors, and health systems are recalibrating their approach to preventative care and longevity. Personalised medicine has long promised transformation, but its application in nutrition and day-to-day health has remained inconsistent, often segmented across diagnostics, apps, and unregulated wellness products.

By launching this system in Abu Dhabi—a city increasingly positioning itself as a hub for health innovation—the partners are tapping into rising regional interest in medical tourism, precision healthcare, and national bio-sovereignty initiatives. The Emirati Genome Programme and investments in infrastructure such as the Abu Dhabi BioBank and Malaffi health data network have already laid the groundwork for a data-integrated, proactive care model. M42’s involvement effectively connects this programme to a real-world delivery pathway, with precision nutrition as its spearhead.

In parallel, the global nutrition and supplements industry is undergoing intense scrutiny as regulators and consumers demand evidence-based validation. This has created a strategic opening for platforms like 10XREVIV, which go beyond biomarker tracking to offer interventional care grounded in science and delivered via clinician infrastructure.

The rise of GLP-1 drugs for obesity, the ageing population’s growing interest in longevity, and a cultural pivot toward optimisation over illness all point to a future where wellness is no longer optional but embedded in preventive health strategies. By embedding diagnostics, AI, supplementation, and medical-grade IV care in one framework, 10XREVIV provides a real-time case study in how these trends are operationalised.

What are the clinical components of the 10XREVIV ecosystem, and how will it be implemented?

Beyond the headline announcement, the partners are planning a multi-layered deployment. This includes the launch of a flagship Precision Longevity clinic in Abu Dhabi, designed to provide hands-on care using the 10XREVIV protocols. Additionally, a randomised controlled trial (RCT) will evaluate the effects of genetically informed IV nutrition in managing Type 2 diabetes, a chronic disease with metabolic roots and rising prevalence in the region.

Further down the pipeline is the development of a clinician training curriculum to embed precision nutrition and genetic literacy into standard care. This curriculum aims to translate complex genomic insights into accessible clinical decision-making tools, thereby helping healthcare professionals across M42’s network adopt these emerging modalities.

In practical terms, the model works as a closed-loop diagnostic-to-intervention system. Patients are first assessed using genetic, blood, and lifestyle data. Based on this, they receive a health report and a care plan that includes supplements, dietary adjustments, or IV protocols. These interventions are then administered or overseen by certified medical teams, with follow-up and biomarker reassessment closing the loop.

This delivery model sidesteps many of the weaknesses of direct-to-consumer wellness products, which often lack clinician oversight, evidence-backed calibration, or continuity of care. By institutionalising the experience, 10XREVIV adds credibility, compliance, and the potential for longitudinal data capture.

What is the competitive outlook, and how might the initiative evolve?

The entrance of this tri-party venture into the personalised health space could prompt significant ripple effects. Direct competitors in the supplement, IV therapy, and biomarker tracking space may need to scale up their data science and regulatory posture. Conversely, wellness companies that fail to evolve toward clinically grounded models may find themselves squeezed between consumer scepticism and regulatory pressure.

For companies like Thorne HealthTech, Levels, and InsideTracker, which also operate at the biomarker-personalisation frontier, the emergence of an end-to-end clinic-linked model poses new questions about defensibility and scalability. Meanwhile, players in the precision diagnostics or wearables space may find integration with such closed-loop systems to be a growth avenue or acquisition target.

From a strategic viewpoint, Abu Dhabi could serve as a global pilot. If outcomes from the initial RCTs and clinics prove strong, the partners are likely to expand to other high-income, tech-forward regions including Singapore, Saudi Arabia, or European wellness hubs. M42’s broader footprint and credibility also offer a pathway to institutional adoption in health systems rather than just cash-pay consumers.

In the medium term, success will depend on three pillars: the robustness of clinical data from the RCT and patient outcomes, the ability to scale clinician adoption and training, and the creation of sustainable pricing and reimbursement models that allow this to move beyond premium health niches.

Why is this more than a wellness play—and what should the sector learn from it?

What differentiates 10XREVIV from past precision health initiatives is the convergence of science, delivery, and market readiness. Previous efforts in personal genomics or biomarker-based interventions have often been siloed: data without action, supplements without evidence, or AI platforms without human interface. Here, the pipeline moves from DNA to delivery with scientific, operational, and market validation integrated.

The initiative also signals the emergence of a new playbook for health systems and investors. For governments, insurers, and integrated care providers, this type of closed-loop model could reduce long-term costs via prevention and chronic disease management. For investors, it offers a scalable, IP-rich business model with multiple revenue streams spanning diagnostics, therapeutics, and services.

For the sector at large, the takeaway is clear: future growth in wellness and optimisation will depend not on branding alone but on clinically validated, tech-enabled, and integrative systems that blend biotech with delivery infrastructure. The wellness industry, long driven by consumer perception, is becoming a serious contender in healthcare innovation—and 10XREVIV may become the case study of how that transition unfolds.

What are the key takeaways from the 10XREVIV launch and strategic partnership between 10X Health, REVIV Global, and M42

• 10X Health, REVIV Global, and M42 have partnered to launch 10XREVIV in Abu Dhabi, introducing a clinically integrated precision nutrition platform anchored in genetics, biomarkers, and AI.

• The 10X Precision Nutrition System can analyse up to 20 million genetic variants with 99.97 percent accuracy, producing a personalised 400+ page health profile for each user.

• The system delivers personalised interventions, including micronutrient formulations, metabolic weight plans, and IV therapies, all tailored to individual genetic and lifestyle profiles.

• A flagship Precision Longevity clinic will be established in Abu Dhabi, with plans for a randomised controlled trial to evaluate the role of genetically guided IV nutrition in Type 2 diabetes.

• M42’s infrastructure, which includes over 480 healthcare facilities in 26 countries, positions Abu Dhabi as a launchpad for advanced longevity medicine and health optimisation models.

• The partnership reflects broader shifts in global healthcare, where wellness, AI, and biotech are converging to create hybrid delivery platforms focused on healthspan rather than just disease care.

• 10XREVIV offers a potential blueprint for wellness platforms evolving into full-stack, clinically backed ecosystems that blend diagnostics, interventions, and clinician training.

• With demand for personalised health growing and regulatory scrutiny increasing, the collaboration sets a new bar for credibility, scientific grounding, and global expansion in the wellness-tech sector.